Work

KarMMa-4: Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T-Cell Therapy, in High-Risk Newly Diagnosed Multiple Myeloma

Year: 2020

Type: article

Study design: Study Protocol

Source: Blood

DOI: 10.1182/blood-2020-139009

Authors: Saad Z. Usmani, Jesus G. Berdeja, Anna Truppel-Hartmann, Marie-Laure Casadebaig, Honeylet Wortman-Vayn, Suresh G. Shelat, Steven Novick, Nina Shah

Institutions: Levine Cancer Institute, Sarah Cannon, Tennessee Oncology, Bluebird Bio (United States), Bristol-Myers Squibb (Switzerland), Bristol-Myers Squibb (United States), University of California, San Francisco

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3095747334

FWCI: 1.77

Cites:

Cited by: 21

Related to: 10